Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

Taimur Sher; Kena C. Miller; David Lawrence; Amy Whitworth; Francisco Hernandez-Ilizaliturri; Myron S. Czuczman; Austin Miller; William Lawrence; Syed Ali Bilgrami; Raman Sood; Margaret T. Wood; Annemarie W. Block; Kelvin Lee; Asher Alban Chanan-Khan

doi:10.3109/10428190903406806

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

Taimur Sher, Kena C. Miller, David Lawrence, Amy Whitworth, Francisco Hernandez-Ilizaliturri, Myron S. Czuczman, Austin Miller, William Lawrence, Syed Ali Bilgrami, Raman Sood, Margaret T. Wood, Annemarie W. Block, Kelvin Lee, Asher Alban Chanan-Khan

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Article

76 Scopus citations

Abstract

Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.

Original language	English (US)
Pages (from-to)	85-88
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	51
Issue number	1
DOIs	https://doi.org/10.3109/10428190903406806
State	Published - Jan 1 2010

Keywords

Chronic lymphocytic leukemia
Fludarabine-refractory
High-risk cytogenetics
Lenalidomide

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428190903406806

Fingerprint Dive into the research topics of 'Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics'. Together they form a unique fingerprint.

Cite this

Sher, T., Miller, K. C., Lawrence, D., Whitworth, A., Hernandez-Ilizaliturri, F., Czuczman, M. S., Miller, A., Lawrence, W., Bilgrami, S. A., Sood, R., Wood, M. T., Block, A. W., Lee, K., & Chanan-Khan, A. A. (2010). Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leukemia and Lymphoma, 51(1), 85-88. https://doi.org/10.3109/10428190903406806

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. / Sher, Taimur; Miller, Kena C.; Lawrence, David; Whitworth, Amy; Hernandez-Ilizaliturri, Francisco; Czuczman, Myron S.; Miller, Austin; Lawrence, William; Bilgrami, Syed Ali; Sood, Raman; Wood, Margaret T.; Block, Annemarie W.; Lee, Kelvin; Chanan-Khan, Asher Alban.

In: Leukemia and Lymphoma, Vol. 51, No. 1, 01.01.2010, p. 85-88.

Research output: Contribution to journal › Article

Sher, T, Miller, KC, Lawrence, D, Whitworth, A, Hernandez-Ilizaliturri, F, Czuczman, MS, Miller, A, Lawrence, W, Bilgrami, SA, Sood, R, Wood, MT, Block, AW, Lee, K & Chanan-Khan, AA 2010, 'Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics', Leukemia and Lymphoma, vol. 51, no. 1, pp. 85-88. https://doi.org/10.3109/10428190903406806

Sher, Taimur ; Miller, Kena C. ; Lawrence, David ; Whitworth, Amy ; Hernandez-Ilizaliturri, Francisco ; Czuczman, Myron S. ; Miller, Austin ; Lawrence, William ; Bilgrami, Syed Ali ; Sood, Raman ; Wood, Margaret T. ; Block, Annemarie W. ; Lee, Kelvin ; Chanan-Khan, Asher Alban. / Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. In: Leukemia and Lymphoma. 2010 ; Vol. 51, No. 1. pp. 85-88.

@article{7dea72a981a3474c9d6951bc46af16b4,

title = "Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics",

abstract = "Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.",

keywords = "Chronic lymphocytic leukemia, Fludarabine-refractory, High-risk cytogenetics, Lenalidomide",

author = "Taimur Sher and Miller, {Kena C.} and David Lawrence and Amy Whitworth and Francisco Hernandez-Ilizaliturri and Czuczman, {Myron S.} and Austin Miller and William Lawrence and Bilgrami, {Syed Ali} and Raman Sood and Wood, {Margaret T.} and Block, {Annemarie W.} and Kelvin Lee and Chanan-Khan, {Asher Alban}",

year = "2010",

month = jan,

day = "1",

doi = "10.3109/10428190903406806",

language = "English (US)",

volume = "51",

pages = "85--88",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

AU - Sher, Taimur

AU - Miller, Kena C.

AU - Lawrence, David

AU - Whitworth, Amy

AU - Hernandez-Ilizaliturri, Francisco

AU - Czuczman, Myron S.

AU - Miller, Austin

AU - Lawrence, William

AU - Bilgrami, Syed Ali

AU - Sood, Raman

AU - Wood, Margaret T.

AU - Block, Annemarie W.

AU - Lee, Kelvin

AU - Chanan-Khan, Asher Alban

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.

AB - Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.

KW - Chronic lymphocytic leukemia

KW - Fludarabine-refractory

KW - High-risk cytogenetics

KW - Lenalidomide

UR - http://www.scopus.com/inward/record.url?scp=74949083498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949083498&partnerID=8YFLogxK

U2 - 10.3109/10428190903406806

DO - 10.3109/10428190903406806

M3 - Article

C2 - 20055660

AN - SCOPUS:74949083498

VL - 51

SP - 85

EP - 88

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -